<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
      <PMID Version="1">34181360</PMID>
      <DateCompleted>
        <Year>2021</Year>
        <Month>12</Month>
        <Day>09</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2021</Year>
        <Month>12</Month>
        <Day>14</Day>
      </DateRevised>
      <Article PubModel="Print">
        <Journal>
          <ISSN IssnType="Electronic">1533-712X</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>41</Volume>
            <Issue>4</Issue>
            <PubDate>
              <MedlineDate>2021 Jul-Aug 01</MedlineDate>
            </PubDate>
          </JournalIssue>
          <Title>Journal of clinical psychopharmacology</Title>
          <ISOAbbreviation>J Clin Psychopharmacol</ISOAbbreviation>
        </Journal>
        <ArticleTitle>A Phase 3, Placebo-Controlled Trial of Once-Daily Viloxazine Extended-Release Capsules in Adolescents With Attention-Deficit/Hyperactivity Disorder.</ArticleTitle>
        <Pagination>
          <StartPage>370</StartPage>
          <EndPage>380</EndPage>
          <MedlinePgn>370-380</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="doi" ValidYN="Y">10.1097/JCP.0000000000001404</ELocationID>
        <Abstract>
          <AbstractText Label="PURPOSE" NlmCategory="OBJECTIVE">This phase 3 clinical trial evaluated the efficacy and safety of viloxazine extended-release capsules (VLX-ER) as a monotherapy for attention-deficit/hyperactivity disorder (ADHD) in adolescents (12-17 years).</AbstractText>
          <AbstractText Label="METHODS" NlmCategory="METHODS">Eligible subjects (n = 310) were randomized to receive once-daily 200 and 400 mg VLX-ER, or placebo for 6 weeks. The primary efficacy end point was change from baseline (CFB) at the end of study (EOS) in ADHD Rating Scale-5 Total score. Key secondary end points were Clinical Global Impression-Improvement score at EOS, CFB at EOS in Conners 3-Parent Short Form Composite T-score, and CFB at EOS in Weiss Functional Impairment Rating Scale-Parent Total average score.</AbstractText>
          <AbstractText Label="RESULTS" NlmCategory="RESULTS">In the 200-mg/d and 400-mg/d VLX-ER treatment groups, a significant improvement was found in the CFB at EOS in ADHD Rating Scale-5 Total (P = 0.0232, P = 0.0091) and Inattention (P = 0.0424, P = 0.0390) and Hyperactivity/Impulsivity (P = 0.0069, P = 0.0005) subscale scores versus placebo. The Clinical Global Impression-Improvement score was significantly improved at EOS in the 200-mg/d and 400-mg/d VLX-ER groups versus placebo (P = 0.0042, P = 0.0003). The Conners 3-Parent Short Form composite T-score and Weiss Functional Impairment Rating Scale-Parent Total average score exhibited improvement in both VLX-ER groups; however, the difference versus placebo was not statistically significant. The most common treatment-related adverse events were somnolence, headache, decreased appetite, nausea, and fatigue. The adverse event-related discontinuation rates were &lt;5% in all groups.</AbstractText>
          <AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Viloxazine extended-release demonstrated statistically significant and clinically meaningful improvement in ADHD symptoms in adolescents and was generally well tolerated.</AbstractText>
          <CopyrightInformation>Copyright © 2021 The Author(s). Published by Wolters Kluwer Health, Inc.</CopyrightInformation>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Nasser</LastName>
            <ForeName>Azmi</ForeName>
            <Initials>A</Initials>
            <AffiliationInfo>
              <Affiliation>From the Clinical Research.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Liranso</LastName>
            <ForeName>Tesfaye</ForeName>
            <Initials>T</Initials>
            <AffiliationInfo>
              <Affiliation>Biostatistics.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Adewole</LastName>
            <ForeName>Toyin</ForeName>
            <Initials>T</Initials>
            <AffiliationInfo>
              <Affiliation>From the Clinical Research.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Fry</LastName>
            <ForeName>Nicholas</ForeName>
            <Initials>N</Initials>
            <AffiliationInfo>
              <Affiliation>From the Clinical Research.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Hull</LastName>
            <ForeName>Joseph T</ForeName>
            <Initials>JT</Initials>
            <AffiliationInfo>
              <Affiliation>From the Clinical Research.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Busse</LastName>
            <ForeName>Gregory D</ForeName>
            <Initials>GD</Initials>
            <AffiliationInfo>
              <Affiliation>Medical Affairs Departments, Supernus Pharmaceuticals, Inc, Rockville, MD.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Chowdhry</LastName>
            <ForeName>Fatima</ForeName>
            <Initials>F</Initials>
            <AffiliationInfo>
              <Affiliation>From the Clinical Research.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Cutler</LastName>
            <ForeName>Andrew J</ForeName>
            <Initials>AJ</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Psychiatry, SUNY Upstate Medical University, and Neuroscience Education Institute, Lakewood Ranch.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Jones</LastName>
            <ForeName>Nandita Joshi</ForeName>
            <Initials>NJ</Initials>
            <AffiliationInfo>
              <Affiliation>Clinical Research Department, CNS Healthcare, Jacksonville, FL.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Findling</LastName>
            <ForeName>Robert L</ForeName>
            <Initials>RL</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Psychiatry, Virginia Commonwealth University School of Medicine, VA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Schwabe</LastName>
            <ForeName>Stefan</ForeName>
            <Initials>S</Initials>
            <AffiliationInfo>
              <Affiliation>Research and Development, Supernus Pharmaceuticals, Inc, Rockville, MD.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
          <PublicationType UI="D016449">Randomized Controlled Trial</PublicationType>
        </PublicationTypeList>
      </Article>
      <MedlineJournalInfo>
        <MedlineTA>J Clin Psychopharmacol</MedlineTA>
        <NlmUniqueID>8109496</NlmUniqueID>
        <ISSNLinking>0271-0749</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D018759">Adrenergic Uptake Inhibitors</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D003692">Delayed-Action Preparations</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>5I5Y2789ZF</RegistryNumber>
          <NameOfSubstance UI="D014745">Viloxazine</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D000293" MajorTopicYN="N">Adolescent</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000294" MajorTopicYN="Y">Adolescent Behavior</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
          <QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D018759" MajorTopicYN="N">Adrenergic Uptake Inhibitors</DescriptorName>
          <QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName>
          <QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D001289" MajorTopicYN="Y">Attention Deficit Disorder with Hyperactivity</DescriptorName>
          <QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName>
          <QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName>
          <QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D001526" MajorTopicYN="N">Behavioral Symptoms</DescriptorName>
          <QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D003692" MajorTopicYN="N">Delayed-Action Preparations</DescriptorName>
          <QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName>
          <QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D004305" MajorTopicYN="N">Dose-Response Relationship, Drug</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D004311" MajorTopicYN="N">Double-Blind Method</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D016903" MajorTopicYN="N">Drug Monitoring</DescriptorName>
          <QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D011569" MajorTopicYN="N">Psychiatric Status Rating Scales</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D063189" MajorTopicYN="N">Symptom Assessment</DescriptorName>
          <QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D014745" MajorTopicYN="Y">Viloxazine</DescriptorName>
          <QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName>
          <QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName>
        </MeshHeading>
      </MeshHeadingList>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="entrez">
          <Year>2021</Year>
          <Month>6</Month>
          <Day>28</Day>
          <Hour>12</Hour>
          <Minute>41</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2021</Year>
          <Month>6</Month>
          <Day>29</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2021</Year>
          <Month>12</Month>
          <Day>15</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">34181360</ArticleId>
        <ArticleId IdType="pmc">PMC8244935</ArticleId>
        <ArticleId IdType="doi">10.1097/JCP.0000000000001404</ArticleId>
        <ArticleId IdType="pii">00004714-202107000-00006</ArticleId>
      </ArticleIdList>
      <ReferenceList>
        <Reference>
          <Citation>Xu G Strathearn L Liu B, et al. . Twenty-year trends in diagnosed attention-deficit/hyperactivity disorder among US children and adolescents, 1997–2016. JAMA Netw Open. 2018;1:e181471.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6324288</ArticleId>
            <ArticleId IdType="pubmed">30646132</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Brahmbhatt K Hilty DM Hah M, et al. . Diagnosis and treatment of attention deficit hyperactivity disorder during adolescence in the primary care setting: a concise review. J Adolesc Health. 2016;59:135–143.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5576000</ArticleId>
            <ArticleId IdType="pubmed">27209327</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Holbrook JR Cuffe SP Cai B, et al. . Persistence of parent-reported ADHD symptoms from childhood through adolescence in a community sample. J Atten Disord. 2016;20:11–20.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4474771</ArticleId>
            <ArticleId IdType="pubmed">24994874</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Barkley RA. Adolescents with attention-deficit/hyperactivity disorder: an overview of empirically based treatments. J Psychiatr Pract. 2004;10:39–56.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">15334986</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wolraich ML Wibbelsman CJ Brown TE, et al. . Attention-deficit/hyperactivity disorder among adolescents: a review of the diagnosis, treatment, and clinical implications. Pediatrics. 2005;115:1734–1746.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">15930238</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Baweja R, Mattison RE, Waxmonsky JG. Impact of attention-deficit hyperactivity disorder on school performance: what are the effects of medication? Paediatr Drugs. 2015;17:459–477.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">26259966</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Scholtens S, Rydell AM, Yang-Wallentin F. ADHD symptoms, academic achievement, self-perception of academic competence and future orientation: a longitudinal study. Scand J Psychol. 2013;54:205–212.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">23510262</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Barkley RA, Cox D. A review of driving risks and impairments associated with attention-deficit/hyperactivity disorder and the effects of stimulant medication on driving performance. J Safety Res. 2007;38:113–128.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">17303170</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Shaw M Hodgkins P Caci H, et al. . A systematic review and analysis of long-term outcomes in attention deficit hyperactivity disorder: effects of treatment and non-treatment. BMC Med. 2012;10:99.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3520745</ArticleId>
            <ArticleId IdType="pubmed">22947230</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Biederman J Monuteaux MC Mick E, et al. . Young adult outcome of attention deficit hyperactivity disorder: a controlled 10-year follow-up study. Psychol Med. 2006;36:167–179.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">16420713</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wolraich ML Hagan JF Jr. Allan C, et al. . Clinical practice guideline for the diagnosis, evaluation, and treatment of attention-deficit/hyperactivity disorder in children and adolescents. Pediatrics. 2019;144:1–25.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">32111626</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Childress AC. Methylphenidate HCL for the treatment of ADHD in children and adolescents. Expert Opin Pharmacother. 2016;17:1171–1178.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">27114115</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Childress A, Tran C. Current investigational drugs for the treatment of attention-deficit/hyperactivity disorder. Expert Opin Investig Drugs. 2016;25:463–474.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">26814173</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Biederman J, Mick E, Faraone SV. Age-dependent decline of symptoms of attention deficit hyperactivity disorder: impact of remission definition and symptom type. Am J Psychiatry. 2000;157:816–818.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">10784477</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Chen MH, Tsai SJ. Treatment-resistant panic disorder: clinical significance, concept and management. Prog Neuropsychopharmacol Biol Psychiatry. 2016;70:219–226.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">26850787</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Mattingly GW Weisler RH Young J, et al. . Clinical response and symptomatic remission in short- and long-term trials of lisdexamfetamine dimesylate in adults with attention-deficit/hyperactivity disorder. BMC Psychiatry. 2013;13:39.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3568402</ArticleId>
            <ArticleId IdType="pubmed">23356790</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Newcorn JH Kratochvil CJ Allen AJ, et al. Atomoxetine/Methylphenidate Comparative Study Group . Atomoxetine and osmotically released methylphenidate for the treatment of attention deficit hyperactivity disorder: acute comparison and differential response. Am J Psychiatry. 2008;165:721–730.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">18281409</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wilens TE Gignac M Swezey A, et al. . Characteristics of adolescents and young adults with ADHD who divert or misuse their prescribed medications. J Am Acad Child Adolesc Psychiatry. 2006;45:408–414.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">16601645</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Clemow DB. Misuse of methylphenidate. Curr Top Behav Neurosci. 2017;34:99–124.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">26695166</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kroutil LA Van Brunt DL Herman-Stahl MA, et al. . Nonmedical use of prescription stimulants in the United States. Drug Alcohol Depend. 2006;84:135–143.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">16480836</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Moran LV Ongur D Hsu J, et al. . Psychosis with methylphenidate or amphetamine in patients with ADHD. N Engl J Med. 2019;380:1128–1138.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6543546</ArticleId>
            <ArticleId IdType="pubmed">30893533</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Schwartz S, Correll CU. Efficacy and safety of atomoxetine in children and adolescents with attention-deficit/hyperactivity disorder: results from a comprehensive meta-analysis and metaregression. J Am Acad Child Adolesc Psychiatry. 2014;53:174–187.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">24472252</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hirota T, Schwartz S, Correll CU. Alpha-2 agonists for attention-deficit/hyperactivity disorder in youth: a systematic review and meta-analysis of monotherapy and add-on trials to stimulant therapy. J Am Acad Child Adolesc Psychiatry. 2014;53:153–173.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">24472251</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hennissen L Bakker MJ Banaschewski T, et al. ADDUCE consortium . Cardiovascular effects of stimulant and non-stimulant medication for children and adolescents with ADHD: a systematic review and meta-analysis of trials of methylphenidate, amphetamines and atomoxetine. CNS Drugs. 2017;31:199–215.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5336546</ArticleId>
            <ArticleId IdType="pubmed">28236285</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bushe CJ, Savill NC. Systematic review of atomoxetine data in childhood and adolescent attention-deficit hyperactivity disorder 2009–2011: focus on clinical efficacy and safety. J Psychopharmacol. 2014;28:204–211.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">23438503</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hammerness P McCarthy K Mancuso E, et al. . Atomoxetine for the treatment of attention-deficit/hyperactivity disorder in children and adolescents: a review. Neuropsychiatr Dis Treat. 2009;5:215–226.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2695220</ArticleId>
            <ArticleId IdType="pubmed">19557116</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kolar D Keller A Golfinopoulos M, et al. . Treatment of adults with attention-deficit/hyperactivity disorder. Neuropsychiatr Dis Treat. 2008;4:389–403.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2518387</ArticleId>
            <ArticleId IdType="pubmed">18728745</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Asherson P Bushe C Saylor K, et al. . Efficacy of atomoxetine in adults with attention deficit hyperactivity disorder: an integrated analysis of the complete database of multicenter placebo-controlled trials. J Psychopharmacol. 2014;28:837–846.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4230847</ArticleId>
            <ArticleId IdType="pubmed">25035246</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Montoya A Hervas A Cardo E, et al. . Evaluation of atomoxetine for first-line treatment of newly diagnosed, treatment-naive children and adolescents with attention deficit/hyperactivity disorder. Curr Med Res Opin. 2009;25:2745–2754.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">19785510</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Charach A, Fernandez R. Enhancing ADHD medication adherence: challenges and opportunities. Curr Psychiatry Rep. 2013;15:371.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3718998</ArticleId>
            <ArticleId IdType="pubmed">23712722</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Biederman J Fried R DiSalvo M, et al. . Evidence of low adherence to stimulant medication among children and youths with ADHD: an electronic health records study. Psychiatr Serv. 2019;70:874–880.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">31242830</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Pinder RM Brogden RN Speight TM, et al. . Viloxazine: a review of its pharmacological properties and therapeutic efficacy in depressive illness. Drugs. 1977;13:401–421.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">324751</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Garcia-Olivares J, Schwabe S, Yu CP. Effects of viloxazine on central neurotransmitter systems: a microdialysis study in freely moving rats. Poster presented at: American Society for Experimental Neurotherapeutics Annual Meeting, March 2–5, 2020, Bethesda, MD.</Citation>
        </Reference>
        <Reference>
          <Citation>Yu C Garcia-Olivares J Candler S, et al. . New insights into the mechanism of action of viloxazine: serotonin and norepinephrine modulating properties. J Exp Pharmacol. 2020;12:285–300.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC7473988</ArticleId>
            <ArticleId IdType="pubmed">32943948</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Nasser A Liranso T Adewole T, et al. . A phase III, randomized, placebo-controlled trial to assess the efficacy and safety of once-daily SPN-812 (viloxazine extended-release) in the treatment of attention-deficit/hyperactivity disorder in school-age children. Clin Ther. 2020;42:1452–1466.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">32723670</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Johnson JK Liranso T Saylor K, et al. . A phase II double-blind, placebo-controlled, efficacy and safety study of SPN-812 (extended-release viloxazine) in children with ADHD. J Atten Disord. 2020;24:348–358.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6939319</ArticleId>
            <ArticleId IdType="pubmed">30924702</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sheehan DV Sheehan KH Shytle RD, et al. . Reliability and validity of the Mini International Neuropsychiatric Interview for Children and Adolescents (MINI-KID). J Clin Psychiatry. 2010;71:313–326.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">20331933</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>DuPaul GJ Power TJ Anastopoulos AD, et al. . ADHD Rating Scale-5 for Children and Adolescents: Checklists, Norms, and Clinical Interpretation. New York, NY: The Guilford Press; 2016.</Citation>
        </Reference>
        <Reference>
          <Citation>Guy W. Clinical Global Impression (CGI). Early Clinical Drug Evaluation Unit (ECDEU) Assessment Manual for Psychopharmacology. Rockville, MD: U.S. Department of Health, Education, and Welfare; Public Health Service, Alcohol, Drug Abuse, and Mental Health Administration; National Institute of Mental Health; Psychopharmacology Research Branch; Division of Extramural Research Programs; 1976:218–222.</Citation>
        </Reference>
        <Reference>
          <Citation>Sparrow EP. Essentials of Conners Behavior Assessments. Hoboken, NJ: John Wiley &amp; Sons, Inc.; 2010.</Citation>
        </Reference>
        <Reference>
          <Citation>Gajria K Kosinski M Sikirica V, et al. . Psychometric validation of the Weiss Functional Impairment Rating Scale—Parent Report Form in children and adolescents with attention-deficit/hyperactivity disorder. Health Qual Life Outcomes. 2015;13:184.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4650258</ArticleId>
            <ArticleId IdType="pubmed">26577642</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Thompson T Lloyd A Joseph A, et al. . The Weiss Functional Impairment Rating Scale-Parent Form for assessing ADHD: evaluating diagnostic accuracy and determining optimal thresholds using ROC analysis. Qual Life Res. 2017;26:1879–1885.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5486894</ArticleId>
            <ArticleId IdType="pubmed">28220338</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Posner K Brown GK Stanley B, et al. . The Columbia-Suicide Severity Rating Scale: initial validity and internal consistency findings from three multisite studies with adolescents and adults. Am J Psychiatry. 2011;168:1266–1277.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3893686</ArticleId>
            <ArticleId IdType="pubmed">22193671</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Goodman D Faraone SV Adler LA, et al. . Interpreting ADHD Rating Scale scores: linking ADHD Rating Scale scores and CGI levels in two randomized controlled trials of lisdexamfetamine dimesylate in ADHD. Primary Psychiatry. 2010;17:44–52.</Citation>
        </Reference>
        <Reference>
          <Citation>Mattingly GW, Anderson RH. Optimizing outcomes in ADHD treatment: from clinical targets to novel delivery systems. CNS Spectr. 2016;21:45–59.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">28044946</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Steele M, Jensen PS, Quinn DM. Remission versus response as the goal of therapy in ADHD: a new standard for the field? Clin Ther. 2006;28:1892–1908.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">17213010</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Buitelaar JK Montgomery SA van Zwieten-Boot BJ, European College of Neuropsychopharmacology Consensus C . Attention deficit hyperactivity disorder: guidelines for investigating efficacy of pharmacological intervention. Eur Neuropsychopharmacol. 2003;13:297–304.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">12888190</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hughes A Williams MR Lipari RN, et al. . Prescription Drug Use and Misuse in the United States: Results From the 2015 National Survey on Drug Use and Health. Rockville, MD: SAMHSA, Center for Behavioral Health Statistics and Quality, National Survey on Drug Use and Health; 2015. Available at: https://www.samhsa.gov/data/sites/default/files/NSDUH-FFR2-2015/NSDUH-FFR2-2015.htm. Accessed November 19, 2020.</Citation>
        </Reference>
        <Reference>
          <Citation>Weyandt LL Oster DR Marraccini ME, et al. . Pharmacological interventions for adolescents and adults with ADHD: stimulant and nonstimulant medications and misuse of prescription stimulants. Psychol Res Behav Manag. 2014;7:223–249.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4164338</ArticleId>
            <ArticleId IdType="pubmed">25228824</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Swanson JM Elliott GR Greenhill LL, et al. . Effects of stimulant medication on growth rates across 3 years in the MTA follow-up. J Am Acad Child Adolesc Psychiatry. 2007;46:1015–1027.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">17667480</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Punja S Shamseer L Hartling L, et al. . Amphetamines for attention deficit hyperactivity disorder (ADHD) in children and adolescents. Cochrane Database Syst Rev. 2016;2:CD009996.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">26844979</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Biederman J, Spencer T, Wilens T. Evidence-based pharmacotherapy for attention-deficit hyperactivity disorder. Int J Neuropsychopharmacol. 2004;7:77–97.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">14733627</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Pliszka S, Issues AWGoQ . Practice parameter for the assessment and treatment of children and adolescents with attention-deficit/hyperactivity disorder. J Am Acad Child Adolesc Psychiatry. 2007;46:894–921.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">17581453</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Mattingly GW Wilson J Ugarte L, et al. . Individualization of attention-deficit/hyperactivity disorder treatment: pharmacotherapy considerations by age and co-occurring conditions. CNS Spectr. 2020;1–20.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">32054558</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bangs ME Tauscher-Wisniewski S Polzer J, et al. . Meta-analysis of suicide-related behavior events in patients treated with atomoxetine. J Am Acad Child Adolesc Psychiatry. 2008;47:209–218.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">18176331</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Faraone SV Schachar RJ Barkley RA, et al. . Early morning functional impairments in stimulant-treated children with attention-deficit/hyperactivity disorder versus controls: impact on the family. J Child Adolesc Psychopharmacol. 2017;27:715–722.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5651955</ArticleId>
            <ArticleId IdType="pubmed">28394175</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Cutler AJ, Mattingly GW. Beyond the pill: new medication delivery options for ADHD. CNS Spectr. 2017;22:463–474.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">28683846</ArticleId>
          </ArticleIdList>
        </Reference>
      </ReferenceList>
    </PubmedData>
  </PubmedArticle>
</PubmedArticleSet>
